Related Experiment Videos
Roads from vaccines to therapies
Leonard A Smith1, Melody J Jensen, Vicki A Montgomery
1Division of Toxinology and Aerobiology, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 21702-5011, USA. leonard.smith@amedd.army.mil
Summary
Recombinant botulinum neurotoxin fragment C shows promise as a safe and effective next-generation vaccine. Research is also exploring botulinum toxin light chains for therapeutic interventions against botulism.
Area of Science:
- Biotechnology
- Immunology
- Microbiology
Background:
- Botulinum neurotoxin (BoNT) poses a significant health threat.
- Current vaccines have limitations, necessitating improved alternatives.
- Recombinant BoNT fragments have demonstrated immunogenicity in preclinical models.
Purpose of the Study:
- To develop and evaluate recombinant BoNT fragment C as a next-generation vaccine candidate.
- To establish manufacturing processes for purified recombinant vaccines.
- To explore therapeutic interventions for botulism using BoNT light chains.
Main Methods:
- Synthetic genes encoding carboxyl-terminal regions of BoNT types A, B, C1, E, and F were expressed in Pichia pastoris.
- Manufacturing processes were optimized for high-purity vaccine production.
- Recombinant BoNT light chains were expressed in Escherichia coli for therapeutic screening.
Main Results:
- Recombinant vaccines were safe, efficacious, and stable, suitable for industrial production.
- Purified vaccines are being produced under current Good Manufacturing Practices for clinical trials.
- Proteolytically active BoNT light chains are utilized in high-throughput screening for inhibitors.
Conclusions:
- Recombinant fragment C is a viable candidate for a next-generation botulism vaccine.
- Developed manufacturing processes support large-scale production for clinical use.
- Resources from vaccine development are being repurposed for novel botulism therapies.